Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medivolve Inc MEDVF

Medivolve Inc. is a Canadian healthcare technology company. The Company and its subsidiaries, Medivolve Pharmacy Inc. (doing business as Marbella Pharmacy) and Kedy Ying Jao D.O., a Medical Corporation, operate a distributed network of two retail patient-care locations in California, United States. It has two business units: Medivolve Pharmacy Division (MPD) and Medivolve Clinic Services... see more

OTCPK:MEDVF - Post Discussion

Medivolve Inc > More good news...$$$
View:
Post by GeneralWolfe on Apr 08, 2022 9:48am

More good news...$$$

Medivolve webinar : Confirmed 200-300mil revenue for 2022, Q4 2021 had $55 mil recievables, significant collection of recievables has occurred with expectation of a max $1.6 mil deduction for bad recievables. Q1 2022 is 'good' comparative to Q4 2021 $180 per patient at the moment. Average revenue per patient per year $1-$2k. (Cross reference to medivolve database of patients they’d have in theory over $1B in recurring revenue) Closest timeline for Telehealth is 3 months for beta test (maybe) and 6 months for commercial. David Preiner is CEO to develop a telehealth business, not to manage a bunch of testing sites. Management believes the stock is significantly undervalued, but can't do anything (considering a share buyback, not a confirmation). New hire Vincent will be handling PR from now on....$$$$$, get in while its dirt cheap...
Comment by deepoil0808 on Apr 08, 2022 4:14pm
Problem is that NO ONE TRUSTS THEM. I will point out a few points: (a)  They never told the market that they were under regulatory review, this is material news. (b)  Imagine how disorganized the operations were when you have one (1) person processing $ 55 million in receivables and getting them rejected because they were not filled out properly.   This reaks of incompetence ...more  
Comment by Catspajamas on Apr 08, 2022 5:37pm
Still salty, boring and transparent! Oh... and PODA!!! Bahahawawawawa!!!!
Comment by Abovetheflay on Apr 11, 2022 12:03pm
I ask AGAIN, why do you waste your time posting on a stock you don't own?  You must have a motive...I am guessing it is the same old tale.  You are a paid to bash the stock.... Your speculation is at best odd and certainly not accurate.  This leads me back to my first thought...you are a paid basher.  
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities